Morgan Stanley Infla Rx N.V. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Infla Rx N.V. stock. As of the latest transaction made, Morgan Stanley holds 2,038,166 shares of IFRX stock, worth $3.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,038,166
Previous 668,131
205.05%
Holding current value
$3.83 Million
Previous $1.02 Million
396.58%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding IFRX
# of Institutions
34Shares Held
13.6MCall Options Held
30.9KPut Options Held
2.1K-
Suvretta Capital Management, LLC New York, NY5.73MShares$10.8 Million0.59% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$3.89 Million0.37% of portfolio
-
Northern Trust Corp Chicago, IL667KShares$1.25 Million0.0% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL638KShares$1.2 Million0.0% of portfolio
-
Ubs Oconnor LLC Chicago, IL626KShares$1.18 Million0.1% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $83.1M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...